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Abstract
To validate the EQ-5D-5L health-related quality of life (HrQoL) questionnaire in
adolescents and young adults with posttraumatic stress disorder (PTSD) after sexual
and/or physical abuse. We used data from a randomized controlled trial of 87
participants with PTSD aged 14–21 years. The discriminative ability was evaluated
by comparing participants scores on the descriptive system of the EQ-5D-5L with
general population scores. Furthermore, the discriminative ability between sub-
groups of participants with different disease severity levels was estimated. Corre-
lations between the EQ-5D index and clinical parameters were used to measure
construct validity. Test-retest reliability was measured by intraclass correlation
coefficients (ICC) between baseline, posttreatment and 3-month follow-up scores
of participants with stable symptoms. Finally, the responsiveness of the EQ-5D was
calculated by mean differences, effect sizes and receiver operating characteristic
(ROC) analyses for participants with improved symptoms. Participants reported
significantly more problems on the dimensions “mobility”, “usual activities”,
“pain/discomfort” and “anxiety/depression” than the general population. The EQ-
5D-5L was able to discriminate between different disease severity levels. The EQ-
5D index and clinical scales were significantly correlated with absolute values of
correlation coefficients varying between 0.21 and 0.59. Furthermore, ICCs between
0.65 and 0.91 indicated good test-retest reliability for the EQ-5D index. The ICCs
for the EQ-VAS between baseline and 3-month follow-up, and posttreatment and 3-
month follow-up were statistically significant with 0.71 and 0.87, respectively,
whereas the ICC between baseline and posttreatment was 0.08 and not statistically
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significant. Effect sizes to measure the responsiveness ranged between −0.008 and
0.40 for the EQ-5D index and − 0.32 and 0.40 for the EQ-VAS. Furthermore, the
area under the curve in ROC analyses was between 0.40 and 0.64 for the EQ-5D
index and 0.60 and 0.70 for the EQ-VAS. Discriminative ability, test-retest reli-
ability and construct validity of the EQ-5D-5L were good, whereas the responsive-
ness was rather weak. Nevertheless, the EQ-5D-5L can be used to measure HrQoL
in adolescents and young adults with PTSD. German Clinical Trials Register
identifier: DRKS00004787; date of registration: 18th March 2013; https://www.
drks.de
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Background
Various studies address the high prevalence of sexual and/or physical abuse in children and
adolescents and the mental consequences [1]. Studies estimate that 30% to 40% of sexually
and/or physically abused children and adolescents develop posttraumatic stress disorder
(PTSD) symptoms afterwards [2]. Patients with PTSD suffer from intrusive reliving of the
traumatic event, and avoid stimuli associated with the trauma. Furthermore, patients show
symptoms of hyperarousal, like difficulty in concentrating, hyper-vigilance or exaggerated
startle response [3]. Consequences of PTSD are long-term and restrict the social life of
patients. Thus, literature reported a reduced health related quality of life (HrQoL) of patients
with PTSD [4–7].
In general, two methodological approaches to measure HrQoL can be distinguished.
Symptoms and immediate consequences of the disease are captured by disease specific
instruments, whereas generic instruments evaluate universal domains of HrQoL. Thus,
disease specific instruments evaluate HrQoL in more detail, whereas generic instru-
ments are used to compare HrQoL across different diseases, which is important to
estimate quality-adjusted life years (QALYs) in health economic evaluations.
A frequently used generic instrument is the EQ-5D-5L [8, 9]. The EQ-5D-5L consists of
five items addressing the dimensions ‘mobility’, ‘self-care’, ‘usual activities’, ‘pain/discom-
fort’, and ‘anxiety/depression’. Patients are asked to rate their problems in each dimension on
an ordinal scale with the five levels “no problems”, “slight problems”, “moderate problems”,
“severe problems” or “extreme problems”.
The usefulness of the EQ-5D-5L in measuring HrQoL can be evaluated by assessing its
psychometric properties, comprising of the discriminative ability, construct validity, test-retest
reliability and responsiveness. The discriminative ability refers to the ability of the instrument
to discriminate between health states. The construct validity verifies whether the instrument
measures what it is supposed to measure. The test-retest reliability is the ability to reproduce a
result consistently in time, and the responsiveness examines the instrument’s reaction to
changes in HrQoL.
Although psychometric properties of the EQ-5D for several mental disorders like
schizophrenic disorders, anxiety disorders and social phobia have been analysed [10],
those have not been evaluated for patients with PTSD yet. Therefore, this study aims
to evaluate psychometric properties of the EQ-5D-5L in adolescents and young adults
with PTSD.
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Methods
Study Design and Participants
We used data collected within a multicentre randomized controlled trial (RCT) with adoles-
cents and young adults with PTSD aged 14–21 years [11]. A primary diagnosis of abuse–
related PTSD (with a lowered diagnostic threshold of two instead of three avoidance symp-
toms) was required for inclusion. Furthermore, participants had to have a sufficient knowledge
of German language as well as safe living conditions. Participants with current severe
suicidality or severe and life-threatening suicidality or self-harming behaviour within the last
6 month, IQ ≤ 75, current substance dependence (abstinence <6 months), or a substance-
induced disorder, any documented pervasive developmental disorder, lifetime psychotic or
bipolar disorder (unclear cases were included) according to the DSM-IV-TR [3], as well as
simultaneous psychotherapeutic treatment, were excluded. Recruitment took place at German
university outpatient clinics. At baseline (T0), no or a stable psychopharmacological treatment
(≥ 3 weeks) was required. After intake participants were randomized either to a Developmen-
tally adapted Cognitive Processing Therapy arm (D-CPT) or wait-list condition with treatment
advice (WL/TA). Participant were re-evaluated subsequently at the end of treatment (T1,
mean: 173 days after study entry; SD 42) and three months after the end of treatment (T2;
mean: 261 days after study entry; SD 49). A detailed description of study design and
treatments analysed in the RCT can be found elsewhere [11, 12]. The trial has been approved
by the Ethics Committee of Catholic University Eichstätt-Ingolstadt, Frei Universitaet Berlin,
and Goethe University Frankfurt, and is conducted according to the ICH Guideline for Good
Clinical Practice.
Health-Related Quality of Life
The EQ-5D-5L questionnaire was used to assess HrQoL [8, 9]. With the EQ-5D descriptive
system, participants were asked to rate their health problems in the five dimensions ‘mobility’,
‘self-care’, ‘usual activities’, ‘pain/discomfort’ and ‘anxiety/depression’ on an ordinal five
level scale with “no problems (1)”, “slight problems (2)”, “moderate problems (3)” , “severe
problems (4)” or “extreme problems (5)”. Answers were combined to health states with
“11111” and “55555” representing the best and worst health state, respectively. Overall,
3125 (55) possible EQ-5D-5L health states exist. The EQ-5D index was calculated for the
health state of each PTSD patient, such that health states were transformed to a scale between
−0.661 representing the worst possible HrQoL, 0 representing death and 1 representing the
best possible HrQoL using preference-based value sets derived from the German general
population [13]. In addition to the descriptive system and EQ-5D index, HrQoL was assessed
on the visual analogue scale of the EQ-5D (EQ-VAS). Participant were asked to rate their
HrQoL visually between 0 (worst) and 100 (best HrQoL) [8]. For the current analyses, only
participants with information on the EQ-5D-5L were included (n = 87).
Socio-Demographics and Clinical Parameters
Socio-demographic variables included individual characteristics (e.g. age, gender) as well as
family background, living situation and education. PTSD severity was measured by the
clinical interview Clinician Administered PTSD Scale for Children and Adolescents (CAPS-
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CA) [14, 15], which rates frequency and intensity of PTSD symptoms on an ordinal scale
ranging between 0 (never/none) to 4 (daily or almost daily/extreme with a total score ranging
from 0 to 136). Additionally, self-reported PTSD symptoms were measured by the University
of California Los Angeles PTSD Reaction Index (UCLA) with its total score ranging from 0 to
68 [16, 17]. Additionally, participants completed the Youth Self Report (YSR) with its total
score ranging from 0 to 202 [18, 19]. The occurrence of borderline symptoms was measured
by the Borderline Symptoms List-23 (BSL-23) (total score between 0 and 92) [20] and
depressive symptoms were evaluated by the Beck Depression Inventory II (BDI-II) (total
score between 0 and 63) [21, 22].
Statistical Analysis
Statistical analysis comprised the (1) discriminative ability, (2) construct validity, (3) test-retest
reliability, and (4) responsiveness of the EQ-5D-5L. Baseline data was used to assess the
discriminative ability and the construct validity. Baseline, T1 and T2 data was used to test the
test-retest reliability and the responsiveness of the EQ-5D-5L.
As the discriminative ability represents the ability to discriminate between different health
states [23], the EQ-5D-5L scores of participants at baseline were compared with scores of the
general population. These were taken from a telephone survey of 5005 adults representative
for the German general population (≥ 18 years old) [24]. As participants with PTSD were aged
14–21 years, we only included general population respondents the age ≤ 21 (n = 257). In
addition, the ability of the EQ-5D-5L to distinguish between different severity levels of PTSD
was tested by subgroups depending on the CAPS-CA total score (n = 83). Subgroups were
built based on tertiles of the CAPS-CA total scores with CAPS-CA total scores between 17
and 56 (n = 29), 57–73 (n = 27) and 74–113 (n = 27), respectively. Differences in the descrip-
tive system scores of the EQ-5D-5L based on different severities of disease were tested by χ2-
tests (α ≤ 0.05). Differences in the EQ-5D index and the EQ-VAS were tested using Mann-
Whitney-U-tests (α ≤ 0.05).
The construct validity, i.e. the ability of the EQ-5D-5L to describe the underlying construct,
which was assumed to be represented by PTSD and comorbid symptoms, was tested [25].
Baseline data was used to calculate correlations between symptoms scales (CAPS-CA, UCLA-
PTSD-RI, YSR, BSL and BDI-II total score) and the EQ-5D index and EQ-VAS. As neither
the EQ-5D index nor the EQ-VAS was distributed normally we used non-parametric Spear-
man rank correlation coefficients (rs). Small, moderate and large conformity between the EQ-
5D index or the EQ-VAS and the CAPS-CA, UCLA, YSR, BSL and BDI-II total score were
defined as 0.1 < |rs| ≤ 0.3, 0.3 < |rs| ≤ 0.5 and |rs| > 0.5, respectively [26].
The test-retest reliability was tested to investigate changes in the EQ-5D-5L between the
different measurement points anchored by “no changes” in PTSD symptoms [25, 27].
Following previous literature [26, 28], “no changes” in the CAPS-CA total score between
different measurement points were defined as CAPS-CA total score differences smaller than
0.5 standard deviations of the CAPS-CA score at baseline (±10.85 points on the CAPS-CA
score). Intraclass correlation coefficients (ICCs) for EQ-5D index and EQ-VAS values were
calculated with “no changes” between different measurement points. Similarity was assumed
for an ICC ≥0.7 [25].
Responsiveness determines the ability of the EQ-5D-5L to detect changes in health states
over time [29]. Thereby, changes between the different measurement points were anchored by
“improvements” in PTSD symptoms, which were defined as CAPS-CA total score differences
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of more than 0.5 standard deviations of the CAPS-CA score at baseline. Mean differences of
the EQ-5D index and EQ-VAS between the different measurement points were calculated and
significance of “improvements” was tested by t-tests (α ≤ 0.05). Mean differences were
standardized by the standard deviation at baseline to derive effect sizes (ES) or the standard
deviation at the particular measurement point, T1 or T2, to derive standardized response means
(SRM). According to Cohen, 0.1 ≤ |ES| or |SRM| < 0.2 represented almost no changes,
0.2 ≤ |ES| or |SRM| < 0.5 represented small changes, 0.5 ≤ |ES| or |SRM| < 0.8 represented
medium changes and |ES| or |SRM| ≥ 0.8 represented large changes [26]. Finally, a receiver
operating characteristic (ROC) analysis was conducted [30]. ROC analysis specifies whether
participants with “improvements” in the CAPS-CA total score also improve in the EQ-5D
index and the EQ-VAS. An instrument with perfect discrimination has an area under the curve
(AUC) of 1.0, whereas random detection of changes will have an AUC of 0.5.
Results
Sample Characteristics
Sample characteristics are shown in Table 1. At baseline participants had a mean age of 18.1
(SD 2.3) years. Most of the participants were female (85%, n = 74) and were living at home
with their parents (56%, n = 49). Smaller proportions of participants were living alone (15%,
n = 13) or with other adolescents or young adults (18%, n = 16). Only 13% (n = 11) had
achieved an A-level exam, because most of the participants had not quitted school yet due to
their young age.
Table 1 Sample characteristics (n = 87)
Demographics
age mean | SD 18.1 2.3
male gender n | % 13 14.9
A-level exam or higher n | % 11 12.6
number of siblings mean | SD 2.3 2.0
Living situation
alone mean | SD 13 14.9
with parents mean | SD 49 56.3
emergency accommodation on mean | SD 2 2.3
foster family mean | SD 4 4.6
shared living mean | SD 16 18.4
Symptom Severity
UCLA total score mean | SD 42.1 12.2
CAPS-CA total score mean | SD 64.7 21.7
YSRs total score mean | SD 71.7 21.9
BSL mean | SD 37.1 18.6
BDI-II mean | SD 29.1 13.8
Health related quality of life
EQ-5D index mean | SD 0.70 0.25
EQ-VAS mean | SD 61.0 21.8
SD: standard derivation; n: number; %: percent
UCLA: University of California Los Angeles PTSD Reaction Index; CAPS-CA: Clinical Administered PTSD
Scale for Children and Adolescent; YSR: Youth Self Report; BSL: Borderline Symptoms List-23; BDI-II: Beck
Depression Inventory II;
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Clinical Characteristics
The mean severity of PTSD measured by the CAPS-CA and UCLA total score was 64.7 (SD
21.7) and 42.1 (SD 12.2), respectively. The mean YSR total score was 71.7 (SD 21.9).
Furthermore, the mean BDI-II score was 29.1 (SD 13.8) and mean BSL score was 37.1 (SD
18.6).
The mean EQ-5D index was 0.7 (SD 0.3). Furthermore, participants reported a mean EQ-
VAS of 61.0 (SD 21.8). Further details on socio-demographics and clinical characteristics are
shown in Table 1.
Discriminative Ability
Participants reported statistically significant more problems compared with persons of the
general population on all dimensions of the EQ-5D descriptive system except self-care
(Supplementary material: Fig. S1). 90% of the participants with PTSD reported problems
due to anxiety/depression compared with only 24% of the persons of the general population.
Problems due to pain/discomfort were reported by 74% of the participants with PTSD. Even
though persons of the general population reported problems due to pain/discomfort less often
(46%), this dimension of the EQ-5D descriptive system was impaired most frequently in the
general population. Likewise, participants with PTSD had more problems in the dimensions
usual activities and mobility (57% and 29% compared with 17% and 10%, respectively).
The ability of the EQ-5D-5L to distinguish between different severity levels of PTSD was
tested. Participants with higher CAPS-CA total scores had lower EQ-5D index and EQ-VAS
scores (Table 2). All correlations between the EQ-5D index and the CAPS-CA total score were
statistically significant, whereas the EQ-VAS and CAPS-CA were only significantly correlated
for CAPS-CA total scores between 57 and 73. Furthermore, the association between CAPS-
CA total score and EQ-5D-5L descriptive system was not statistically significant.
Construct Validity
The EQ-5D index and the EQ-VAS were statistically significantly correlated with the CAPS-
CA, as well as with the BDI-II and BSL scale (Table 3). Furthermore, the UCLA was
statistically significantly correlated with the EQ-5D index, but not with the EQ-VAS. Thereby,
|rs| ranged between 0.50 and 0.59 for the EQ-5D index and 0.21 and 0.40 for the EQ-VAS.
Table 2 Discriminative ability: Descriptive statistics of the EQ-5D descriptive system, EQ-VAS and the EQ-5D
index by disease severity at baseline















17–56 29 6 1 11 17 21 0.85** 69.62
57–73 27 7 3 17 19 22 0.71*** 59.93**
74–113 27 11 1 19 25 26 0.53* 52.88
SE: standard error; n: number; %: percent; Mann-Whitney-U-test p-value * ≤ 0.05
CAPS-CA: Clinical Administered PTSD Scale for Children and Adolescent
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Test-Retest Reliability
ICCs were calculated to determine the test-retest reliability of the EQ-5D index and EQ-VAS
anchored by “no changes” in the CAPS-CA total score (Table 4). Associations between
different measurement points for the EQ-5D index were statistically significant with an ICC
between 0.65 and 0.91. Associations between T2 and baseline or T1 for the EQ-VAS were
statistically significant with an ICC between 0.71 and 0.87, respectively, whereas the associ-
ation between baseline and T1 was not statistically significant.
Responsiveness
Analysis of responsiveness was anchored by “improvements” in the CAPS-CA total scores (≤
−10.85 points) and quantified by mean differences, ESs and SRMs of the EQ-5D index and
EQ-VAS between the different measurement points (Table 5). Changes in the EQ-5D index
between baseline and T1 were statistically significant with a mean difference of 0.09 (SD
0.11), an ES of 0.40 and a SRM of 0.78. Changes in the EQ-5D index between T1 and T2
were also statistically significant with mean difference of 0.04 (SD 0.09), an ES of 0.14 and a
SRM of 0.44, whereas changes between baseline and T2 were not statistically significant.
Furthermore, changes in the EQ-VAS were not statistically significant. ROC analyses revealed
AUCs between 0.40 and 0.64 for the EQ-5D index and 0.60 and 0.70 for the EQ-VAS.
Table 3 Construct validity: Spearman rank correlation between EQ-5D index, EQ-VAS and scores of other
instruments at baseline (n = 87)






n: number; Spearman rank correlation p-value * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001
CAPS-CA: Clinical Administered PTSD Scale for Children and Adolescent; YSR: Youth Self Report; BSL:
Borderline Symptoms List-23; BDI-II: Beck Depression Inventory II;
Table 4 Test-retest reliability: Intraclass correlation coefficient (ICC) of the EQ-5D index and EQ-VAS
anchored by “no changes” of the CAPS-CA total score (differences smaller than 0.5 standard deviations of the
CAPS-CA score at baseline, which was equal to ±10.85 points on the CAPS-CA score)
ICC
Measurement points n EQ-5D index EQ-VAS
Baseline – T1 10 0.73** 0.08
T1 – T2 30 0.91*** 0.87***
Baseline – T2 8 0.65* 0.71*
n: number; Intraclass correlation coefficient p-value * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001
T1: posttreatment; T2: 3-month follow-up
CAPS-CA: Clinical Administered PTSD Scale for Children and Adolescent;
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Discussion
Discriminative Ability
As expected, participants with higher CAPS-CA total scores had lower EQ-5D index and EQ-VAS
scores and reported more problems on the EQ-5D descriptive system, thus HrQoL was associated
with the severity of PTSD. Compared with the general population participants with PTSD reported
more problems in the dimensions anxiety/depression, pain/discomfort and usual activities. As
participants with PTSD often suffer from pain/discomfort and anxiety/depression [31], likewise in
adults [32], such impairments were expected for adolescents and young adults. Furthermore,
literature reported impairments of HrQoL for adults with PTSD in daily life/social relationships,
spare time activities and autonomy [33]. Thus, problems with usual activities were likely caused by
direct consequences of PTSD. In contrast to mental comorbidities like anxiety/depression partici-
pants rarely suffer from somatic comorbidities due to their young age. Therefore, problemswith self-
care were expected to be low and similar to those of the general population.
The EQ-5D index was able to discriminate between different severities of PTSD, whereas
the EQ-VAS was associated with the severity of PTSD only for participants with moderate
CAPS-CA total scores. As this comparison strongly relies on the groups built, different group
sizes were tested by using quartiles instead of tertiles as threshold for the CAPS-CA total
score. However, results remained insignificant. Therefore, we expect the EQ-VAS to be less
able to discriminate between different severities of PTSD than the EQ-5D index. As suggested
for other mental disorders like schizophrenia or anxiety disorders before [10], it is more likely
that the EQ-VAS addresses different concepts of HrQoL than clinical scales. However,
differences in the discriminative ability between the EQ-5D index and EQ-VAS for partici-
pants with CAPS-CA total scores in the first and third tertile were difficult to explain.
Construct Validity
The EQ-5D indexwas correlatedwith the CAPS-CA,UCLA,YSR, BDI-II total score, and the BSL
total score, whereas the EQ-VAS was correlated with all clinical scales except the UCLA.
According to Cohen, conformity was large between the EQ-5D index and clinical scales because
all Spearman rank correlations |rs| were statistically significant and > 0.5 [26]. Conformity between
the EQ-VAS and the CAPS-CA total score, YSR and BSL were moderate with 0.3 < |rs| ≤ 0.5 and
Table 5 Responsiveness: Improvement of health status measured by the EQ-5D index and EQ-VAS anchored by
the CAPS-CA total score (<−10.25 points)
Mean differences (SD) Effect size (ES) Standardized response mean
(SRM)
Measurement points n EQ-5D index EQ-VAS EQ-5D index EQ-VAS EQ-5D index EQ-VAS
Baseline – T1 47 0.09 (0.11)* 8.9 (28.1) 0.40 0.40 0.78 0.32
T1 – T2 21 0.04 (0.09)* 0.8 (11.6) 0.14 0.04 0.44 0.07
Baseline – T2 43 −0.02 (0.19) −7.0 (18.6) −0.008 −0.32 −0.09 −0.38
n: number; SD: standard derivation; t-test p value * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001
T1: posttreatment; T2: 3-month follow-up
CAPS-CA: Clinical Administered PTSD Scale for Children and Adolescent;
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small between the EQ-VAS and BDI-II total score with 0.3 ≤ |rs|. Interestingly, no conformity was
found between the EQ-VAS and UCLA total score, even though the EQ-VAS was moderately
correlated with the CAPS-CA total score. The CAPS-CA and UCLA are both able to measure
symptoms of PTSD in children, adolescents and young adults based on the DSM-V criteria [34],
thus differences in correlation with the EQ-VAS may rather be due to the different type of
assessment. As the UCLA is a self-rated questionnaire, whereas the CAPS-CA is a clinician-rated
interview, different perceptions of PTSD symptoms may influence correlations.
Test-Retest Reliability
ICCs for the EQ-5D index and EQ-VAS for all pairwise comparisons of different measure-
ment points anchored by “no changes” in the CAPS-CA were statistically significant, except
for the comparison of the EQ-VAS between baseline and T1. Thereby, the EQ-VAS varied
more in the CAPS-CA total score between baseline and T1 than the EQ-5D index. As the
sample size of participants with “no changes” on the CAPS-CA total score between baseline
and T1 was rather small (n = 10) and most of these participants were in the WL/TA condition
(n = 8), results may be unreliable and further research is needed. Nevertheless, the test-retest
reliability for both, the EQ-5D index and EQ-VAS, was good.
Responsiveness
The EQ-5D index was able to represent improvements of the CAPS-CA total score
between baseline and T1, which were clinically meaningful, as mean differences
exceeded published threshold of minimal clinically important differences of the EQ-5D
index for adults with PTSD of 0.05 to 0.08 [35]. However, for all other interactions
between CAPS-CA improvements either changes in the EQ-5D index between measure-
ment points were statistically insignificant or ES and SRM indicated no changes.
Additionally, AUCs of ROC analyses ranged between 0.4 and 0.7, thus CAPS-CA
improvements were hardly represented by the EQ-5D index or the EQ-VAS values. As
treatment effects may be captured more precisely by symptom scales of PTSD than
generic HrQoL measures, the CAPS-CA scale may be more sensitive to capture im-
provements compared with the EQ-5D. Overall, the responsiveness of the EQ-5D index
and the EQ-VAS was weak, which might be caused by the treatment effects themselves
and the small sample size of the study. In particular, as most WL/TA participants did not
receive any treatment, changes between baseline, T1 and T2 were small, thus most of the
participants did not improve in the CAPS-CA total score and were therefore not included
in the responsiveness analysis.
Strength and Limitations
Our studywas based on the EQ-5D-5L, for which value sets were published recently to calculate the
EQ-5D index [13]. Previously the EQ-5D-3Lwas available to determineHrQoL by rating problems
on an ordinal scale with three levels. This version was extended to an ordinal scale with five levels,
which therefore enables to evaluate HrQoLmore precisely. Thus, this version is expected to replace
the commonly used version of the EQ-5D-3L and will be of high relevance for future research.
Furthermore, literature on HrQoL for adolescents and young adults with PTSD was lacking. Only
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one study reported data on HrQoL for children with PTSD aged between 9 and 11 years measuring
the Life Satisfaction Scale [36].
However, our study has several limitations. First, the sample size of n= 87was small, thus results
might be preliminary, calling for further research. Second, participants with PTSD and persons of
the general population differed in age. Participants with PTSD were aged between 14 and 21 years,
whereas persons of the general population were between 18 and 21 years old. As we expect that
HrQoL for younger persons is better or equal compared to older persons, younger persons of the
general population would increase the discriminative ability of the EQ-5D-5L. Finally, mean
differences, ESs and SRMs indicated a low responsiveness for the EQ-5D index and EQ-VAS,
thus the EQ-5D might not represent small changes in clinical symptoms over time.
Conclusion
The EQ-5D-5L is a valid instrument to measure HrQoL in adolescents and young adults with
PTSD. The discriminative ability, the construct validity, and the test-retest reliability were
good, whereas the responsiveness was rather weak.
Acknowledgements We would like to thank all involved patients and therapists for their participation.
Authors’ Contributions ER, RS, BR, RR and HHK conceived the study and developed the design. JD was
responsible for the analysis and wrote the first draft. All authors contributed to the revision and final approval.
Funding Information Open Access funding provided by Projekt DEAL. This study was supported by grants
from the German Ministry of Education and Research (grant numbers 01KR1204D, 01KR1204A, and
01KR1204C).
Data Availability Data from patients cannot be accessed by anyone who is not part of the research team due to
ethical and confidentiality concerns.
Compliance with Ethical Standards
Ethics Approval and Consent to Participate The trial has been approved by the Ethics Committee of Catholic
University Eichstätt-Ingolstadt, the Freie Universitaet Berlin, and the Goethe University Frankfurt and is
conducted according to the ICH Guideline for Good Clinical Practice. Written informed consent was obtained
from all participants and from parents or guardians of minors.
Consent for Publication Written informed consent was obtained from all participants and from parents or
guardians of minors.
Competing Interests RR reported being paid fees for workshops and presentations on posttraumatic stress
disorder (PTSD) treatment and coauthoring a book on cognitive processing therapy. RS reported being paid fees
for workshops and presentations on PTSD treatment. No other disclosures were reported.
Abbreviations AUC, Area under the curve; BDI-II, Beck Depression Inventory II; BSL-23, Border-
line Symptoms List-23; CAPS-CA, Clinician Administered PTSD Scale for Children and Adolescents;
D-CPT, Developmentally Adapted Cognitive Processing Therapy; EQ-5D, EuroQoL-5 Dimension;
468 Psychiatric Quarterly (2021) 92:459–471
EQ-VAS, Visual Analogue Scale of the EQ-5D; ES, Effect sizes; HrQoL, Health related quality of life;
ICC, Intraclass correlation coefficient; PTSD, Posttraumatic stress disorder; ROC, Receiver operating
characteristic; SRM, Standardized response means; UCLA, University of California Los
Angeles PTSD Reaction Index;WL/TA,Wait-list condition with treatment advice; YSR, Youth Self Report
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and
indicate if changes were made. The images or other third party material in this article are included in the article's
Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included
in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy
of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Gilbert R, Widom CS, Browne K, Fergusson D, Webb E, Janson S. Burden and consequences of child
maltreatment in high-income countries. Lancet. 2009;373:68–81.
2. McLaughlin KA, Koenen KC, Hill ED, Petukhova M, Sampson NA, Zaslavsky AM, et al. Trauma
exposure and posttraumatic stress disorder in a national sample of adolescents. J Am Acad Child Adolesc
Psychiatry. 2013;52:815–830.e814.
3. APA (American Psychiatric Assosication). Diagnostisches und Statistisches Manual Psychischer Störungen
- Textversion - DSM-IV-TR. Göttingen: Hogrefe; 2003.
4. Ferry FR, Bolton D, Bunting BP, O’Neill SM, Murphy SD, Devine B. The economic impact of post
traumatic stress disorder in Northern Ireland. 2012.
5. Ferry FR, Brady SE, Bunting BP, Murphy SD, Bolton D, O’Neill SM. The economic burden of PTSD in
Northern Ireland. J Trauma Stress. 2015;28:191–7.
6. Gospodarevskaya E, Segal L. Cost-utility analysis of different treatments for post-traumatic stress disorder
in sexually abused children. Child Adolesc Psychiatry Ment Health. 2012;6.
7. Mihalopoulos C, Magnus A, Lal A, Dell L, Forbes D, Phelps A. Is implementation of the 2013 Australian
treatment guidelines for posttraumatic stress disorder costeffective compared to current practice? A cost-
utility analysis using QALYs and DALYs. Australian New Zealand J Psychiatry. 2014;49:360–76.
8. Group EuroQoL. EuroQol–a new facility for the measurement of health-related quality of life. Health
Policy. 1990;16:199–208.
9. von der Schulenburg J, Claes C, Greiner W, Uber A. Die deutsche Version des EuroQol-Fragebogens. Z
Gesundh Wiss. 1998;6:3–20.
10. Brazier J, Connell J, Papaioannou D, Mukuria C, Mulhern B, Peasgood T, Jones ML, Paisley S, O'Cathain
A, Barkham M, et al. A systematic review, psychometric analysis and qualitative assessment of generic
preference-based measures of health in mental health populations and the estimation of mapping functions
from widely used specific measures. Health Technol Assess 2014, 18:vii-viii, xiii-xxv, 1–188.
11. Rosner R, Konig HH, Neuner F, Schmidt U, Steil R. Developmentally adapted cognitive processing therapy
for adolescents and young adults with PTSD symptoms after physical and sexual abuse: study protocol for a
randomized controlled trial. Trials. 2014;15:195.
12. Rosner R, Rimane E, Frick U, Gutermann J, Hagl M, Renneberg B, et al. Effect of developmentally adapted
cognitive processing therapy for youth with symptoms of posttraumatic stress disorder after childhood
sexual and physical abuse: a randomized clinical trial. JAMA Psychiat. 2019;76:484–91.
13. Ludwig K, Graf von der Schulenburg JM, Greiner W. German value set for the EQ-5D-5L.
Pharmacoeconomics. 2018;36:663–74.
14. Nader K, Kriegler J, Blake D, Pynoos R. Clinical administered PTSD scale, child and adoloescent version
(CAPS-C). White River Junction: National Center for PTSD; 1994.
15. Steil R, Füchsel G. IBS-KJ. Interviews zu Belastungsstörungen bei Kindern und Jugendlichen. Diagnostik
der aktuen und der posttraumatischen Belastungsstörung. Göttingen: Hogrefe; 2006.
16. Steinberg AM, Brymer MJ, Decker KB, Pynoos RS. The University of California at Los Angeles post-
traumatic stress disorder reaction index. Curr Psychiatry Rep. 2004;6:96–100.
17. Ruf M, Schauer M, Elbert T. UPID - UCLA PTSD index for DSM IV. Göttingen: Hogrefe; 2010.
18. Achenbach TM. Manual for the youth self-report and 1991 profile. Burlington: University of Vermont,
Department of Psychiatry; 1991.
469Psychiatric Quarterly (2021) 92:459–471
19. Döpfner M. Fragebogen für Jugendliche; deutsche Bearbeitung der Youth-Self Report Form der Child
Behavior Checklist (YSR). Köln: Arbeitsgruppe Kinder-, Jugend- und Familiendiagnostik; 1998.
20. Bohus M, Kleindienst N, Limberger MF, Stieglitz RD, Domsalla M, Chapman AL, et al. The short version
of the borderline symptom list (BSL-23): development and initial data on psychometric properties.
Psychopathology. 2009;42:32–9.
21. Beck A, Steer R, Brown G. Manual for the Beck depression inventory-II. San Antonio: The Psychological
Corporation; 1996.
22. Hautzinger M, Keller F, Kühner C. BDI-II: Beck depressions-Inventar revision. Frankfurt: Harcourt Test
Services; 2006.
23. Luo X, Cappelleri JC. A practical guide on incorporating and evaluating patient-reported outcomes in
clinical trials. Clin Res Regul Aff. 2008;25:197–211.
24. Grupp H, Konig HH, Konnopka A. Health care utilisation and costs in the general population in Germany.
Health Policy. 2016;120:159–69.
25. Streiner DL, Norman GR. Health measurment scales: a practical guide to their development and use. Oxfort:
Oxford University Press; 2008.
26. Cohen J: Statistical power analysis for the behavioral sciences. Hillsdale: Erlbaum Associates; 1988.
27. Walters SJ. Quality of life outcomes in clinical trials and health-care evaluation: a practical guide to analysis
and interpretation. Chichester: Wiley; 2009.
28. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the
remarkable universality of half a standard deviation. Med Care. 2003;41:582–92.
29. Revicki DA, Gnanasakthy A, Weinfurt K. Documenting the rationale and psychometric characteristics of
patient reported outcomes for labeling and promotional claims: the PRO evidence dossier. Qual Life Res.
2007;16:717–23.
30. Fawcett T. An introduction to ROC analysis. Pattern Recogn Lett. 2006;27:861–74.
31. Brady KT, Killeen TK, Brewerton T, Lucerini S. Comorbidity of psychiatric disorders and posttraumatic
stress disorder. J Clin Psychiatry. 2000;61(Suppl 7):22–32.
32. Haagsma JA, Polinder S, Olff M, Toet H, Bonsel GJ, van Beeck EF. Posttraumatic stress symptoms and
health-related quality of life: a two year follow up study of injury treated at the emergency department.
BMC Psychiatry. 2012;12:1.
33. Monson E, Brunet A, Caron J. Domains of quality of life and social support across the trauma spectrum. Soc
Psychiatry Psychiatr Epidemiol. 2015;50:1243–8.
34. Association AP. Diagnostic and statistical manual of mental disorders. 5th edn. Washington, DC; 2013.
35. Le QA, Doctor JN, Zoellner LA, Feeny NC. Minimal clinically important differences for the EQ-5D and
QWB-SA in post-traumatic stress disorder (PTSD): results from a doubly randomized preference trial
(DRPT). Health Qual Life Outcomes. 2013;11:59.
36. Gillies D, Taylor F, Gray C, O'Brien L, D'Abrew N. Psychological therapies for the treatment of post-
traumatic stress disorder in children and adolescents. Cochrane Database Syst Rev. 2012;12:Cd006726.
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Judith Dams , PhD, is a senior researcher at the Department of Health Economics and Health Services Research
at the Medical Centre Hamburg-Eppendorf, Germany. She is interested in health economic evaluations of
treatment of psychological and neurological disorders.
Eline Rimane , Dipl.-Psych, is a research assistant at the Department of Psychology at the Catholic University
Eichstätt-Ingolstadt. Her research focuses on therapies for adolescents and young adults with post-traumatic
stress disorder.
Prof Regina Steil is the assistant professor of the Department of Clinical Psychology and Psychotherapy at the
Goethe University Frankfurt. Her research focuses pathological health anxieties, post-traumatic stress disorder,
social phobia, emotion regulation and images in childhood and adolescents.
Prof Babette Renneberg is the director of the Department of Clinical Psychology and Psychotherapy at the Frei
Universität Berlin. Her research focuses social cognition and interaction, emotional regulation and cognitive
control and clinical-psychological intervention research.
470 Psychiatric Quarterly (2021) 92:459–471
Prof Rita Rosner is the director of the Department of Psychology at the Catholic University Eichstätt-Ingolstadt.
Her research focuses on therapies for post-traumatic stress disorder in adolescents and young adults and
prolonged grief.
Prof Hans-Helmut König , MPH, is the director of the Department of Health Economics and Health Services
Research at the Medical Centre Hamburg-Eppendorf, Germany. He is interested in health economic evaluations
of health services for individuals with psychological or age-related disorders.
Affiliations
Judith Dams1 & Eline Rimane2 & Regina Steil3 & Babette Renneberg4 & Rita Rosner2 &
Hans-Helmut König1
1 Department of Health Economics and Health Services Research, Hamburg Center for Health Economics
(HCHE), University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
2 Department of Psychology, Catholic University Eichstätt-Ingolstadt, Eichstätt, Germany
3 Department of Clinical Psychology and Psychotherapy, Institute of Psychology, Goethe University
Frankfurt, Frankfurt, Germany
4 Department of Clinical Psychology and Psychotherapy, Freie Universitaet Berlin, Berlin, Germany
471Psychiatric Quarterly (2021) 92:459–471
